Skip to main content
. 2025 Jul 25;17(7):5698–5709. doi: 10.62347/VIOT6629

Table 5.

Comparison of clinical data between patients with different curative effects

Group Effective group (n=223) Ineffective group (n=69) t/χ2 P
Age 43.78±7.75 49.99±6.81 6.392 <0.001
Gender 0.044 0.834
    Male 126 (56.50) 38 (55.07)
    Female 97 (43.50) 31 (44.93)
BMI 23.89±1.50 24.18±1.49 1.380 0.170
Course of disease 4.57±1.49 4.34±1.50 1.135 0.246
Tooth position 1.201 0.753
    Second premolar 39 (17.49) 10 (14.49)
    First molar 79 (35.43) 22 (31.88)
    Second molar 75 (33.63) 28 (40.58)
    Other 30 (13.45) 9 (13.04)
Planting site 1.357 0.244
    Maxillary 89 (39.91) 33 (47.83)
    Lower jaw 134 (60.09) 36 (52.17)
Postprandial gargle 22.643 <0.001
    Yes 118 (52.91) 14 (20.29)
    No 105 (47.09) 55 (79.71)
History of smoking 20.544 <0.001
    Yes 92 (41.26) 50 (72.46)
    No 131 (58.74) 19 (27.54)
History of alcohol consumption 0.584 0.445
    Yes 89 (39.91) 24 (34.78)
    No 134 (60.09) 45 (65.22)
History of diabetes 21.635 <0.001
    Yes 81 (36.32) 47 (68.12)
    No 142 (63.68) 22 (31.88)
Baseline inflammatory marker level
    TNF-α 150.54±19.97 161.19±19.79 3.902 <0.001
    IL-6 492.66±53.02 481.34±52.33 1.566 0.119

Note: BMI, Body Mass Index; TNF-α, Tumor Necrosis Factor-alpha; IL-6, Interleukin-6.